Home Stock

Stock Research: Aspen Pharmacare

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Aspen Pharmacare

JNB:APN ZAE000066692
37
  • Value
    76
  • Growth
    36
  • Safety
    Safety
    39
  • Combined
    42
  • Sentiment
    35
  • 360° View
    360° View
    37
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Aspen Pharmacare Holdings Limited is a global pharmaceutical company. It focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets, including the key brands Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine. Aspen Pharmacare Holdings Limited operates in South Africa and other global markets. In the last fiscal year, the company had a market cap of $2,813 million, profits of $1,070 million, revenue of $2,458 million, and 8,867 employees.

more

ANALYSIS: With an Obermatt 360° View of 37 (better than 37% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aspen Pharmacare are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Aspen Pharmacare. Only the consolidated Value Rank has an attractive rank of 76, which means that the share price of Aspen Pharmacare is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 76% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 36, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 39, meaning the company has a riskier financing structure than 61% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 65% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 35. ...read more

more
Strongest Rank Revenue Growth
Weakest Rank Pro Holdings
Country South Africa
Industry Pharmaceuticals
Size Large
Website aspenpharma.com
Index
JSE All Shares
Aspen Pharmacare stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 91 99 89
Growth
36 27 45 77
Safety
Safety
39 39 41 7
Sentiment
35 71 90 55
360° View
360° View
37 65 88 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
42 73 79 46
Opinions Change
12 23 72 50
Pro Holdings
n/a 80 73 26
Market Pulse
34 70 42 81
Sentiment
35 71 90 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 91 99 89
Growth
36 27 45 77
Safety Safety
39 39 41 7
Combined
42 53 75 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
57 77 82 78
Price vs. Earnings (P/E)
51 97 93 81
Price vs. Book (P/B)
83 89 91 91
Dividend Yield
76 82 81 76
Value
76 91 99 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
7 26 54 78
Profit Growth
63 39 48 76
Capital Growth
11 45 21 21
Stock Returns
80 39 79 79
Growth
36 27 45 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
38 24 34 36
Refinancing
83 88 90 1
Liquidity
26 24 28 24
Safety Safety
39 39 41 7

Similar Stocks

Discover high‑ranked alternatives to Aspen Pharmacare and broaden your portfolio horizons.

Caxton and CTP Publishers and Printers

JNB:CAT
Country: South Africa
Industry: Publishing
Size: Medium
Full Stock Analysis

Impala Platinum

JNB:IMP
Country: South Africa
Industry: Precious Metals & Minerals
Size: Large
Full Stock Analysis

Northam Platinum

JNB:NPH
Country: South Africa
Industry: Precious Metals & Minerals
Size: Large
Full Stock Analysis

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews